Stock Scorecard
Stock Summary for Pyxis Oncology Inc (PYXS) - $1.78 as of 5/29/2026 3:05:23 PM EST
Total Score
8 out of 30
Safety Score
28 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PYXS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PYXS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PYXS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PYXS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for PYXS (28 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 2 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for PYXS
Financial Details for PYXS
Company Overview |
|
|---|---|
| Ticker | PYXS |
| Company Name | Pyxis Oncology Inc |
| Country | USA |
| Description | Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating cancers. The company is headquartered in Cambridge, Massachusetts. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 1.78 |
| Price 4 Years Ago | 1.34 |
| Last Day Price Updated | 5/29/2026 3:05:23 PM EST |
| Last Day Volume | 653,444 |
| Average Daily Volume | 623,427 |
| 52-Week High | 5.55 |
| 52-Week Low | 0.97 |
| Last Price to 52 Week Low | 83.51% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 108.94 |
| Sector PE | 66.00 |
| 5-Year Average PE | -1.39 |
| Free Cash Flow Ratio | 16.18 |
| Industry Free Cash Flow Ratio | 25.30 |
| Sector Free Cash Flow Ratio | 34.59 |
| Current Ratio Most Recent Quarter | 2.76 |
| Total Cash Per Share | 0.11 |
| Book Value Per Share Most Recent Quarter | 0.49 |
| Price to Book Ratio | 3.50 |
| Industry Price to Book Ratio | 15.24 |
| Sector Price to Book Ratio | 23.00 |
| Price to Sales Ratio Twelve Trailing Months | 7.74 |
| Industry Price to Sales Ratio Twelve Trailing Months | 13.16 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.25 |
| Analyst Buy Ratings | 7 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 63,355,000 |
| Market Capitalization | 112,771,900 |
| Institutional Ownership | 33.86% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -2.96% |
| Reported EPS 12 Trailing Months | -1.30 |
| Reported EPS Past Year | -0.37 |
| Reported EPS Prior Year | -1.29 |
| Net Income Twelve Trailing Months | -81,735,000 |
| Net Income Past Year | -79,621,000 |
| Net Income Prior Year | -77,331,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -600.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 7,238,000 |
| Total Cash Past Year | 15,422,000 |
| Total Cash Prior Year | 19,473,000 |
| Net Cash Position Most Recent Quarter | 7,238,000 |
| Net Cash Position Past Year | 15,422,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 53,408,000 |
| Total Stockholder Equity Prior Year | 120,751,000 |
| Total Stockholder Equity Most Recent Quarter | 31,268,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -66,976,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.06 |
| Free Cash Flow Past Year | -63,511,000 |
| Free Cash Flow Prior Year | -57,909,000 |
Options |
|
| Put/Call Ratio | 0.40 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.01 |
| MACD Signal | 0.10 |
| 20-Day Bollinger Lower Band | 0.99 |
| 20-Day Bollinger Middle Band | 1.67 |
| 20-Day Bollinger Upper Band | 2.35 |
| Beta | 1.43 |
| RSI | 43.47 |
| 50-Day SMA | 2.05 |
| 150-Day SMA | 2.48 |
| 200-Day SMA | 2.44 |
System |
|
| Modified | 5/28/2026 11:12:06 PM EST |